Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. $BMRN

Sector Gamma AS increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 43.7% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 175,852 shares of the biotechnology company’s stock after buying an additional 53,504 shares during the period. BioMarin Pharmaceutical accounts for approximately 2.4% of Sector Gamma AS’s portfolio, making the stock its 13th largest holding. Sector Gamma AS owned approximately 0.09% of BioMarin Pharmaceutical worth $9,524,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its stake in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 388 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of BioMarin Pharmaceutical by 207.4% during the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock worth $850,000 after purchasing an additional 8,112 shares in the last quarter. Focus Partners Wealth increased its position in shares of BioMarin Pharmaceutical by 70.2% in the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its stake in BioMarin Pharmaceutical by 33.0% in the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 1,102 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its stake in BioMarin Pharmaceutical by 1.7% in the second quarter. Public Employees Retirement System of Ohio now owns 59,895 shares of the biotechnology company’s stock valued at $3,292,000 after purchasing an additional 988 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $56.21 on Friday. The firm has a fifty day simple moving average of $56.20 and a two-hundred day simple moving average of $56.01. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51. The company has a market capitalization of $10.80 billion, a PE ratio of 21.13, a P/E/G ratio of 0.61 and a beta of 0.27. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.20). The company had revenue of $776.13 million during the quarter, compared to analysts’ expectations of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMRN shares. Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Wells Fargo & Company cut their target price on shares of BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $66.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Barclays lowered their price target on BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Finally, HC Wainwright upped their price objective on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, December 22nd. Seventeen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $90.04.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.